Inspire Medical Investors Face Jan. 5 Deadline to Lead Securities Case Over Inspire V Launch

Plaintiffs say Inspire hid readiness problems around Inspire V, leading to a steep guidance cut followed by a sharp one-day share slide.

Overview

In the pending Minnesota federal case, investors seeking to serve as lead plaintiff must file by January 5, 2026.
The complaints cover purchases between August 6, 2024 and August 4, 2025 and allege misleading assurances of operational readiness for Inspire V.
Plaintiffs cite Medicare claims software updates that took effect only on July 1, 2025, a surplus of older Inspire IV devices at centers, and incomplete training and onboarding.
On August 4, 2025, Inspire disclosed an elongated rollout and cut 2025 EPS guidance by over 80%, and the stock fell $42.04, about 32%, according to the notices.
Hagens Berman, the Law Offices of Howard G. Smith, and the Rosen Law Firm are soliciting investors and whistleblowers, and no class has been certified yet.